During the last three months, 17 analysts shared their evaluations of Blueprint Medicines (NASDAQ:BPMC), revealing diverse outlooks from bullish to bearish. Summarizing their recent assessments, the ...

-- Blueprint Medicines will receive $775 million in upfront payments, comprising $675 million in cash and $100 million equity investment priced at $96.57 per share, and is eligible to receive up to ...

Reni Benjamin, an analyst from JMP Securities, reiterated the Buy rating on Blueprint Medicines (BPMC – Research Report). The associated price target remains the same with $125.00. Discover ...

PARIS and CAMBRIDGE, Mass., June 2, 2025 /PRNewswire/ -- Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic ...

On August 2, Blueprint Medicines, a pharmaceutical company developing medicines for treating cancer and blood diseases, released its financial results for the second quarter of 2023. Blueprint ...

Blueprint Medicines, a Sanofi company, today announced updated data reinforcing the clinical efficacy and safety of long-term ...

The acquisition includes a rare immunology disease medicine and an advanced and early-stage immunology pipeline. Paul Hudson, CEO of Sanofi said, "The proposed acquisition of Blueprint Medicines ...

CAMBRIDGE, Mass., March 3, 2015 -- Blueprint Medicines today announced a strategic collaboration with Alexion to discover, develop and commercialize novel drug candidates for an undisclosed activated ...

-- Achieved 61% year-over-year growth with $149.4 million in AYVAKIT net product revenues in the first quarter 2025 -- -- Raising AYVAKIT net product revenue guidance to $700 - $720 million for 2025 - ...

It looks like this biotech has what big-pharma companies have been eager to acquire. Blueprint Medicine's stock made its biggest leap of the year thanks to data from the Navigator trial in patients ...

So far this year, shares of Blueprint Medicines (BPMC) haven't performed nearly as well as the company's research and development team. The company's already earned FDA approval for two new cancer ...